About this Medicine article

Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study by Waljee, Akbar K; Higgins, Peter D R; Jensen, Camilla B; Villumsen, Marie; Cohen-Mekelburg, Shirley A; Wallace, Beth I; Berinstein, Jeffrey A; Allin, Kristine H; Jess, Tine is a Medicine article available to read on EtoBox.

## Background: Safety of anti-tumour necrosis factor-α (tnfα) therapy in people with a history of cancer and with an immune-mediated disease is unknown. we aimed to assess the risk of recurrence of initial cancer or development of a new primary cancer after treatment with anti-tnfα therapy. ## Methods: In this danish, population-based cohort study we recruited adults (≥18 years) with inflammatory bowel disease (ibd), rheumatoid arthritis, or psoriasis and a primary cancer diagnosed between jan 1, 1999 and dec 31, 2016. patients were recruited from the prospectively recorded danish national patient registry and the danish cancer registry. participants were matched 1:10 between the treatment group who received anti-tnfα therapy and the control group (no anti-tnfα therapy) and we excluded individuals with a cancer diagnosed before their first anti-tnfα treatment (or before matching date for controls), individuals diagnosed with ibd, rheumatoid arthritis, or psoriasis after anti-tnfα initiation (or respective match date for controls), and individuals who received anti-tnfα with fewer than five matched controls. using adjusted cox proportional hazards regression, we estimated the primar

Author

Waljee, Akbar K; Higgins, Peter D R; Jensen, Camilla B; Villumsen, Marie; Cohen-Mekelburg, Shirley A; Wallace, Beth I; Berinstein, Jeffrey A; Allin, Kristine H; Jess, Tine

Publisher

Elsevier ; Elsevier Limited; Elsevier BV (ISSN 2468-1253)

Published

2020

Language

EN

Field

Medicine (Health Sciences)